Genetic Technologies Limited Announces Update On Intellectual Property
Published: Feb 13, 2014
MELBOURNE, AUSTRALIA--(Marketwired - February 12, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO"), dated February 10, 2014 (the "Certificate"). The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013.
"We are pleased to announce the successful resolution of this fourth re-examination of one of our key patents," said Tom Howitt, acting Chief Executive Officer of Genetic Technologies. "This news once again reinforces the strength of the Company's non-coding patent portfolio. Further, given some potential licensees have used the pending re-examination to delay settlement discussions, we expect that good faith negotiations will now resume in earnest."
In the Certificate, the USPTO confirms the patentability of claims 1-15, 17,18, 26-29 and 32 and no amendments have been made to the '179 patent.
About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Tom Howitt
Chief Executive Officer (Acting)
Genetic Technologies Limited
Phone: +61 3 8412 7000
Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103
Help employers find you! Check out all the jobs and post your resume.